JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mack, W. M.
Right arrow Articles by Pessah, I. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mack, W. M.
Right arrow Articles by Pessah, I. N.

Discrimination of multiple binding sites for antagonists of the calcium release channel complex of skeletal and cardiac sarcoplasmic reticulum

WM Mack, I Zimanyi and IN Pessah

Department of Veterinary Pharmacology and Toxicology, University of California, Davis.

The mechanisms by which ruthenium red (RR), neomycin and FLA 365 ([2,6- dichloro-4-aminophenyl]isopropylamine) inhibit calcium channels of skeletal and cardiac sarcoplasmic reticulum (SR) are characterized. Neomycin and FLA 365 inhibit ryanodine-enhanced calcium release from skeletal SR vesicles in a dose-dependent manner. The apparent affinity of [3H]ryanodine is reduced in a dose-dependent manner by each inhibitor indicative of competitive mechanisms. Displacement studies with skeletal and cardiac SR demonstrate that the order of inhibitory potency is RR greater than neomycin greater than FLA 365 and RR greater than FLA 365 greater than neomycin, respectively. Neomycin is 100-fold less potent in cardiac SR and inhibition of [3H]ryanodine binding is biphasic in both tissues. Neomycin induces a greater proportion of [3H]ryanodine binding states recalcitrant to inhibition in cardiac SR. The ability of neomycin to increase the apparent affinity of [3H]ryanodine for its binding sites is potentiated by RR and attenuated by FLA 365. Kinetic binding studies reveal that increasing neomycin concentrations decreases the association of [3H]ryanodine as predicted for competitive inhibition. However, high (much greater than Kn) neomycin increases [3H]ryanodine binding affinity by slowing dissociation of the radioligand demonstrating that, like micromolar ryanodine, neomycin induces allosterism. Studies with combinations of antagonists demonstrate the existence of two non-overlapping inhibitor recognition sites within the ryanoid site, one polycationic inhibitor site and one FLA 365 inhibitor site. These results suggest that aminoglycoside-induced muscle paralysis may be mediated by direct block of pre- and postsynaptic calcium release channels of endoplasmic reticulum.

Volume 262, Issue 3, pp. 1028-1037, 09/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
O. Ostrovskaya, R. Goyal, N. Osman, C. E. McAllister, I. N. Pessah, J. R. Hume, and S. M. Wilson
Inhibition of Ryanodine Receptors by 4-(2-Aminopropyl)-3,5-dichloro-N,N-dimethylaniline (FLA 365) in Canine Pulmonary Arterial Smooth Muscle Cells
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 381 - 390.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. Gafni, P. W. Wong, and I. N. Pessah
Non-coplanar 2,2',3,5',6-Pentachlorobiphenyl (PCB 95) Amplifies Ionotropic Glutamate Receptor Signaling in Embryonic Cerebellar Granule Neurons by a Mechanism Involving Ryanodine Receptors
Toxicol. Sci., January 1, 2004; 77(1): 72 - 82.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Chen, E. Esteve, J.-M. Sabatier, M. Ronjat, M. De Waard, P. D. Allen, and I. N. Pessah
Maurocalcine and Peptide A Stabilize Distinct Subconductance States of Ryanodine Receptor Type 1, Revealing a Proportional Gating Mechanism
J. Biol. Chem., April 25, 2003; 278(18): 16095 - 16106.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Chen, T. F. Molinski, and I. N. Pessah
Bastadin 10 Stabilizes the Open Conformation of the Ryanodine-sensitive Ca2+ Channel in an FKBP12-dependent Manner
J. Biol. Chem., November 12, 1999; 274(46): 32603 - 32612.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
E. M. Balog and E. M. Gallant
Modulation of the sarcolemmal L-type current by alteration in SR Ca2+ release
Am J Physiol Cell Physiol, January 1, 1999; 276(1): C128 - C135.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. Zucchi and S. Ronca-Testoni
The Sarcoplasmic Reticulum Ca2+ Channel/Ryanodine Receptor: Modulation by Endogenous Effectors, Drugs and Disease States
Pharmacol. Rev., March 1, 1997; 49(1): 1 - 52.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. P. Wang, D. H. Needleman, A. B. Seryshev, B. Aghdasi, K. J. Slavik, S.-Q. Liu, S. E. Pedersen, and S. L. Hamilton
Interaction between Ryanodine and Neomycin Binding Sites on Ca[IMAGE] Release Channel from Skeletal Muscle Sarcoplasmic Reticulum
J. Biol. Chem., April 5, 1996; 271(14): 8387 - 8393.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1992 by the American Society for Pharmacology and Experimental Therapeutics.